Ritumab 10 mg/ml (IV Infusion)
500 mg vial: ৳ 55,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Rituximab |
| Company | Drug international ltd |
Indications
- Non-Hodgkin's Lymphoma (NHL)
- Rheumatoid Arthritis (RA)
- Chronic Lymphocytic Leukemia (CLL)
- Granulomatosis with Polyangiitis (GPA)
- Microscopic Polyangiitis (MPA)
- Pemphigus Vulgaris (PV)
Pharmacology
- Genetically engineered chimeric monoclonal antibody
- Directed against the CD20 antigen
- Approximate molecular weight: 145 kD
- Binding affinity for CD20 antigen: 8.0 nM
Dosage & Administration
- Intravenous infusion administration
- First infusion standard rate: 50 mg/hr
- Subsequent infusion standard rate: 100 mg/hr
- Recommended dose for Non-Hodgkin's Lymphoma (NHL): 375 mg/m2
- Recommended dose for Chronic Lymphocytic Leukemia (CLL): 375 mg/m2
- Recommended dose for Rheumatoid Arthritis (RA): Two 1,000 mg intravenous infusions separated by 2 weeks
Interaction
- Formal drug interaction studies not performed
- No alteration in systemic exposure to fludarabine or cyclophosphamide in CLL patients
Contraindications
- Known hypersensitivity to Rituximab or components
Side Effects
- Reactivation of hepatitis B virus
- Fever, rigors, pruritus, skin rashes, dyspnea
- Bronchospasm, angioedema, transient hypotension, flushing
- Asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anemia
- Abdominal pain, bowel obstruction, perforation, exacerbation of heart failure, angina pectoris
- Reversible interstitial pneumonia, interstitial fibrosis, depletion of immunoglobulin concentrations
Pregnancy & Lactation
- Can cause fetal harm when administered to a pregnant woman
- Adverse developmental outcomes in infants exposed to Rituximab in-utero
- Adverse outcomes occur regardless of the mother's health or medication use
- Limited data on Rituximab in human milk and its effect on the breastfed child
- Reported to be excreted at low concentrations in human breast milk
- Women advised not to breastfeed during treatment and 6 months after last dose
Precautions & Warnings
- Can cause severe, including fatal, infusion-related reactions
- Severe mucocutaneous reactions can occur, including fatal outcomes
- Progressive Multifocal Leukoencephalopathy (PML) diagnosis and discontinuation
- Tumor Lysis Syndrome (TLS) management
- Serious, including fatal, bacterial, fungal, and viral infections can occur
Therapeutic Class
- Cytotoxic immunosuppressants
Storage Conditions
- Store in original carton at 2°C-8°C
- Refrigerator storage, do not freeze
- Protect from light and keep out of the reach of children